$7.82
2.36% yesterday
NYSE, Aug 11, 10:00 pm CET
ISIN
US03237H1014
Symbol
AMLX

Amylyx Pharmaceuticals Stock price

$7.82
+0.14 1.82% 1M
+4.42 130.00% 6M
+4.04 106.88% YTD
+5.84 294.95% 1Y
-18.18 69.92% 3Y
-10.25 56.72% 5Y
-10.25 56.72% 10Y
-10.25 56.72% 20Y
NYSE, Closing price Mon, Aug 11 2025
+0.18 2.36%
ISIN
US03237H1014
Symbol
AMLX
Industry

Key metrics

Basic
Market capitalization
$697.3m
Enterprise Value
$493.2m
Net debt
positive
Cash
$204.1m
Shares outstanding
89.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
negative | -
EV/FCF
negative
P/B
3.5
Financial Health
Equity Ratio
85.1%
Return on Equity
-183.1%
ROCE
-114.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$-610.0k | $0.0
EBITDA
$-229.7m | $-163.1m
EBIT
$-230.4m | $-164.6m
Net Income
$-218.9m | $-166.6m
Free Cash Flow
$-243.3m
Growth (TTM | estimate)
Revenue
-100.2% | -100.0%
EBITDA
-1,949.1% | -0.5%
EBIT
-2,152.6% | -0.9%
Net Income
-207.8% | 44.8%
Free Cash Flow
-1,675.7%
Margin (TTM | estimate)
Gross
1,455.4%
EBITDA
37,835.1% | -
EBIT
-
Net
36,055.5% | -
Free Cash Flow
-
More
EPS
$-2.6
FCF per Share
$-2.7
Short interest
9.2%
Employees
384
Rev per Employee
$230.0k
Show more

Is Amylyx Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Amylyx Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Amylyx Pharmaceuticals forecast:

14x Buy
88%
2x Hold
13%

Analyst Opinions

16 Analysts have issued a Amylyx Pharmaceuticals forecast:

Buy
88%
Hold
13%

Financial data from Amylyx Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
-0.61 -0.61
100% 100%
100%
- Direct Costs 8.23 8.23
81% 81%
-
-8.83 -8.83
102% 102%
-
- Selling and Administrative Expenses 72 72
64% 64%
-
- Research and Development Expense 90 90
36% 36%
-
-230 -230
1,949% 1,949%
-
- Depreciation and Amortization 0.75 0.75
38% 38%
-
EBIT (Operating Income) EBIT -230 -230
2,153% 2,153%
-
Net Profit -219 -219
208% 208%
-

In millions USD.

Don't miss a Thing! We will send you all news about Amylyx Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amylyx Pharmaceuticals Stock News

Neutral
Seeking Alpha
4 days ago
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Camille L. Bedrosian - Chief Medical Officer James M.
Neutral
The Motley Fool
5 days ago
Amylyx (AMLX) Q2 Net Loss Narrows 43%
Neutral
Business Wire
5 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results.
More Amylyx Pharmaceuticals News

Company Profile

Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the provision of disease-modifying solutions for neurodegenerative diseases. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Josh Klee
Employees 384
Founded 2013
Website www.amylyx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today